|
|
Analysis of Liu Lanying’s medication rule in the treatment of depression based on Apriori algorithm and complex network |
YANG Jiangwei1 LIANG Wenjie2 LIN Chen3 LIU Lanying1 |
1.Tongde Hospital of Zhejiang Province Mental Health Center of Zhejiang Province, Zhejiang Province, Hangzhou 310012, China;
2.Software College, Fudan University, Shanghai 201203, China;
3.Department of Psychosomatic Medicine, Ningbo First Hospital, Zhejiang Province, Ningbo 315010, China |
|
|
Abstract Objective To explore the medication rule and characteristics of Liu Lanying in the treatment of depression. Methods The data of depression patients treated by Liu Lanying in Tongde Hospital of Zhejiang Province from January 2018 to January 2019 were selected. Frequency analysis, Apriori algorithm and complex network of Gephi software were used to mine the characteristics of core drugs and compatibility. Results Female patient was 75.34%, long course patient was 71.23%, in 73 patients. Reinforcing drugs were 1124 times (51.13%), qi-invigorating drugs were 634 times (26.48%). The top three were Astragali Radix, Pseudostellariae Radix and Acanthopanacis Senticosi Radix et Rhizoma Seu Caulis. The most meridian tropism of drugs were spleen stomach meridian (spleen was 16 times, stomach was nine times). The top three drug compatibility support were Astragali Radix-Pseudostellariae Radix, Glycyrrhizae Radix et Rhizoma-Astragali Radix, Glycyrrhizae Radix et Rhizoma-Pseudostellariae Radix. Core drugs were Astragali Radix, Glycyrrhizae Radix et Rhizoma, Paeoniae Radix Alba, Margaritifera Concha, Pseudostellariae Radix, Polygalae Radix, Acanthopanacis Senticosi Radix et Rhizoma Seu Caulis, Atractylodis Macrocephalae Rhizoma, Cynanchi Paniculati Radix et Rhizoma and Bone Fossil of Big Mammals. Conclusion Liu Lanying’s treatment for depression is based on invigorating spleen and replenishing qi, which is different from dispersing liver, regulating qi, and relieving qi stagnation, which may be related to the gender and course of depression.
|
|
|
|
|
[1] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[2] 王永炎,严世芸.实用中医内科学[M].上海:上海科学技术出版社,2009:468.
[3] 黄秀芳,栗克清,李喜泼,等.重性抑郁障碍患病率的性别差异[J].中国健康心理学杂志,2009,17(1):93-95.
[4] 牛雅娟.《中国抑郁障碍防治指南》药物治疗解读[J].临床药物治疗杂志,2018,16(5):6-8.
[5] 杨蒋伟,朱春青,林晨,等.从脾论治抑郁障碍的理论及临床初探[J].中国医药导报,2019,16(25):130-133.
[6] 苏芮,郭蓉娟,韩振蕴.从中焦论治抑郁症[J].中医学报,2020,35(1):43-45.
[7] 于姚,李阳,刘姝含,等.从脾论治抑郁症的理论基础与现代研究依据[J].山东中医杂志,2020,39(5):445-448.
[8] 王煜,李承德,曲敬蓉,等.黄芪多糖对抑郁大鼠海马NF-κB信号通路的影响[J].中国药理学通报,2018,34(6):836-840.
[9] 孟美黛,冯彦,王鹏,等.茯苓极性提取物对CUMS大鼠神经递质及昼夜节律调节的实验研究[J].中草药,2020, 51(1):118-126.
[10] 林家冉,唐爽,柳红芳.淫羊藿、人参、附子治疗阳光不足型抑郁状态经验——仝小林三味小方撷萃[J].吉林中医药,2020,40(3):296-298.
[11] 杨吉娜.甘草苷抗抑郁作用拟靶向代谢组学和脂质组学研究[D].广州:华南理工大学,2020.
[12] 赵玉娇,高耀,周玉枝,等.白术在神经精神系统疾病中的药理作用及机制研究进展[J].中草药,2017,48(21):4546-4551.
[13] 李传朋,刘玉,魏品球,等.逍遥散及其类方与有效成分抗抑郁作用机制研究进展[J].中国实验方剂学杂志,2020, 26(6):243-250.
[14] 潘菊华,李多娇,王彦云.刺五加抗抑郁作用探析[J].中医学报,2016,31(1):83-86.
[15] 杨文佳,张华海.醒脑解郁方加减对缺血性脑卒中痰瘀阻脑证急性期抑郁的临床研究[J].山东中医杂志,2020, 39(3):236-239,264.
[16] 李梦頔,黄世敬.补益药及其复方制剂抗抑郁作用研究进展[J].中医学报,2017,32(5):818-823.
[17] 丁德正.黄芪建中汤治疗精神疾病举隅[J].河南中医,2016,36(1):19-21.
[18] 莫婷婷,骆超羽.运用黄芪建中汤治疗功能性消化不良合并抑郁症体会[J].云南中医中药杂志,2010,31(3):34-35.
[19] 王元元,邓卫平,李晓强,等.黄芪多糖提高脑卒中后抑郁模型大鼠学习能力的实验观察[J].实验动物与比较医学,2019,39(6):443-448.
[20] 刘丽珠,刘薇,樊琳,等.黄芪多糖对大鼠脑卒中后抑郁的影响[J].中国医药导报,2019,16(7):11-14.
[21] 刘旭恩,沈姣,谢艳丽,等.黄芪甲苷对CUMS抑郁症大鼠模型的血清代谢组学研究[J].免疫学杂志,2018,34(10):829-835,862.
[22] 黄世敬,张永超,张颖.黄芪治疗抑郁症应用与研究[J].世界中医药,2014,9(5):665-668.
[23] 余煊.基于脑内5-HT探讨太子神悦抗抑郁的作用机制[D].北京:清华大学,2017.
[24] 李阳,郭蓉娟,赵钟辉,等.醒脾解郁方对轻中度抑郁症肝郁脾虚证患者的临床疗效研究[J].北京中医药大学学报,2021,44(1):83-91.
[25] 伍桂林,沈默.单味徐长卿治疗神经衰弱150例报告[J].中国民间疗法,1998,12(6):46. |
|
|
|